Next Article in Journal
Donor-Site Morbidity after Fibula Transplantation in Head and Neck Tumor Patients: A Split-Leg Retrospective Study with Focus on Leg Stability and Quality of Life
Next Article in Special Issue
Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms
Previous Article in Journal
Role of Chemokines in the Biology of Cholangiocarcinoma
Previous Article in Special Issue
Body Mass Index and Total Symptom Burden in Myeloproliferative Neoplasms Discovery of a U-shaped Association
Open AccessReview

Splicing Anomalies in Myeloproliferative Neoplasms: Paving the Way for New Therapeutic Venues

1
Inserm, Univ Brest, EFS, UMR 1078, GGB, F-29200 Brest, France
2
Laboratoire d’Hématologie, CHU de Brest, F-29200 Brest, France
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(8), 2216; https://doi.org/10.3390/cancers12082216
Received: 30 June 2020 / Revised: 30 July 2020 / Accepted: 5 August 2020 / Published: 7 August 2020
(This article belongs to the Special Issue New Insights into Myeloproliferative Neoplasms)
Since the discovery of spliceosome mutations in myeloid malignancies, abnormal pre-mRNA splicing, which has been well studied in various cancers, has attracted novel interest in hematology. However, despite the common occurrence of spliceosome mutations in myelo-proliferative neoplasms (MPN), not much is known regarding the characterization and mechanisms of splicing anomalies in MPN. In this article, we review the current scientific literature regarding “splicing and myeloproliferative neoplasms”. We first analyse the clinical series reporting spliceosome mutations in MPN and their clinical correlates. We then present the current knowledge about molecular mechanisms by which these mutations participate in the pathogenesis of MPN or other myeloid malignancies. Beside spliceosome mutations, splicing anomalies have been described in myeloproliferative neoplasms, as well as in acute myeloid leukemias, a dreadful complication of these chronic diseases. Based on splicing anomalies reported in chronic myelogenous leukemia as well as in acute leukemia, and the mechanisms presiding splicing deregulation, we propose that abnormal splicing plays a major role in the evolution of myeloproliferative neoplasms and may be the target of specific therapeutic strategies. View Full-Text
Keywords: splicing; myeloproliferative neoplasm; epigenetic splicing; myeloproliferative neoplasm; epigenetic
Show Figures

Figure 1

MDPI and ACS Style

Hautin, M.; Mornet, C.; Chauveau, A.; Bernard, D.; Corcos, L.; Lippert, E. Splicing Anomalies in Myeloproliferative Neoplasms: Paving the Way for New Therapeutic Venues. Cancers 2020, 12, 2216.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop